JOURNAL ARTICLE

Tocilizumab for severe COVID-19 pneumonia

Brian J. LipworthRory ChanChris RuiWen Kuo

Year: 2020 Journal:   The Lancet Rheumatology Vol: 2 (11)Pages: e660-e660   Publisher: Elsevier BV
Keywords:
Tocilizumab Coronavirus disease 2019 (COVID-19) Pneumonia 2019-20 coronavirus outbreak Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Medicine Virology Betacoronavirus Intensive care medicine Immunology Internal medicine Outbreak Infectious disease (medical specialty) Rheumatoid arthritis Disease

Metrics

5
Cited By
0.11
FWCI (Field Weighted Citation Impact)
7
Refs
0.55
Citation Normalized Percentile
Is in top 1%
Is in top 10%

Citation History

Topics

COVID-19 Clinical Research Studies
Health Sciences →  Medicine →  Infectious Diseases
Long-Term Effects of COVID-19
Health Sciences →  Medicine →  Neurology
SARS-CoV-2 and COVID-19 Research
Health Sciences →  Medicine →  Infectious Diseases

Related Documents

JOURNAL ARTICLE

Tocilizumab for severe COVID-19 pneumonia

Jean‐Jacques MouradPhilippe Azria

Journal:   The Lancet Rheumatology Year: 2020 Vol: 2 (11)Pages: e659-e659
JOURNAL ARTICLE

Late Administration of Tocilizumab for Severe COVID-19 Pneumonia

Pratik ModiStan HoustonSohail EjazBradley BoldizarB. Russelll

Journal:   American Journal of Respiratory and Critical Care Medicine Year: 2025 Vol: 211 (Abstracts)Pages: A6757-A6757
© 2026 ScienceGate Book Chapters — All rights reserved.